List Title | APhA DrugInfoLine

Focus on Anticoagulation Care

SORT BY: Most Recent Most Viewed

October 8, 2019

DOACs are useful for older patients with atrial fibrillation

READ

PREVIEW
According to a retrospective analysis published in the Journal of the American Geriatrics Society, use of direct oral anticoagulants (DOACs) in older patients with nonvalvular atrial...
September 10, 2019

How long should anticoagulation be continued after the first unprovoked VTE?

READ

PREVIEW
The risk of recurrent venous thromboembolism (VTE) appears to increase over time once anticoagulation is stopped in patients with their first unprovoked VTE, with recurrent rates ranging from 10%...
June 25, 2019

Real-time clinical surveillance tool reduces oral anticoagulant adverse events

READ

PREVIEW
According to a study published in the Journal of Patient Safety, implementation of a real-time clinical surveillance tool that provided alerts to pharmacists across 31 hospitals resulted...
April 16, 2019

VTE prophylaxis for high-risk ambulatory patients with cancer

READ

PREVIEW
Use of apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) as thromboprophylaxis in intermediate- to high-risk ambulatory patients receiving chemotherapy for various types of cancers reduced the risk...
February 11, 2019

New data support apixaban over rivaroxaban for newly diagnosed VTE

READ

PREVIEW
Use of apixaban (Eliquis—Bristol–Myers Squibb, Pfizer) appears to be more effective than rivaroxaban (Xarelto—Janssen) for prevention of recurrent venous thromboembolism (VTE) with a decreased...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.